Synapse - Works

Results (260)

Discordance between social vulnerability and cancer-related mortality in border counties - A letter to the editor regarding “local social vulnerability as a predictor for cancer-related mortality among US counties”

Correspondence

LaPelusa, M.; Diaz, F. C.; Santos, P. M. G.; Verduzco-Aguirre, H.; Soto-Perez-de-Celis, E.
The Oncologist (2024)

Fulltext@MSK | Save

A phase I dose-escalation study of LY3405105, a covalent inhibitor of cyclin-dependent kinase 7, administered to patients with advanced solid tumors

Journal Article

Garralda, E.; Schram, A. M.; Bedard, P. L.; Schwartz, G. K.; Yuen, E.; McNeely, S. C.; Ribeiro, S.; Cunningham, J.; Wang, Y.; Urunuela, A.; more...
The Oncologist (2024)

Fulltext@MSK | Save

The weighted toxicity score: Confirmation of a simple metric to communicate toxicity in randomized trials of systemic cancer therapy

Journal Article

Jordan, J.; Maki, R. G.
The Oncologist (2024)

Fulltext@MSK | Save

Characterization and management of adverse reactions in patients with advanced endometrial cancer receiving lenvatinib plus pembrolizumab

Journal Article

Colombo, N.; Lorusso, D.; Monk, B. J.; Slomovitz, B.; Hasegawa, K.; Nogueira-Rodrigues, A.; Zale, M.; Okpara, C. E.; Barresi, G.; McKenzie, J.; more...
The Oncologist (2024)

Fulltext@MSK | Save

Prevalence of enteric infections in patients on immune checkpoint inhibitors and impact on management and outcomes

Journal Article

Magahis, P. T.; Satish, D.; Babady, N. E.; Kamboj, M.; Postow, M. A.; Laszkowska, M.; Faleck, D. M.
The Oncologist (2024)

Fulltext@MSK | Save

Combined RAF and MEK inhibition to treat activated non-V600 BRAF-altered advanced cancers

Journal Article

Rustgi, N.; Maria, A.; Toumbacaris, N.; Zhao, H.; Kargus, K.; Bryant, M.; Waksmundzki, A.; Aricescu, I.; Lefkowitz, R. A.; Li, B. T.; more...
The Oncologist (2024)

Fulltext@MSK | Save

Exocrine pancreatic insufficiency induced by immune checkpoint inhibitors

Journal Article

Satish, D.; Lin, I. H.; Flory, J.; Gerdes, H.; Postow, M. A.; Faleck, D. M.
The Oncologist (2023)

Fulltext@MSK | Save

Phase Ib/II study of the efficacy and safety of binimetinib (MEK162) plus panitumumab for mutant or wild-type RAS metastatic colorectal cancer

Journal Article

Van Cutsem, E.; Yaeger, R.; Delord, J. P.; Tabernero, J.; Siu, L. L.; Ducreux, M.; Siena, S.; Elez, E.; Kasper, S.; Zander, T.; more...
The Oncologist (2023)

Fulltext@MSK | Save

Phase I study of entinostat, atezolizumab, carboplatin, and etoposide in previously untreated extensive-stage small cell lung cancer, ETCTN 10399

Journal Article

Gentzler, R. D.; Villaruz, L. C.; Rhee, J. C.; Horton, B.; Mock, J.; Hanley, M.; Kim, K.; Rudek, M. A.; Phelps, M. A.; Carducci, M. A.; more...
The Oncologist (2023)

Fulltext@MSK | Save

Outcomes of combination platinum-doublet chemotherapy and anti-PD(L)-1 blockade in KRAS(G12C) mutant non-small cell lung cancer

Journal Article

Elkrief, A.; Riccuiti, B.; Alessi, J. V.; Fei, T.; Kalvin, H. L.; Egger, J. V.; Rizvi, H.; Thummalapalli, R.; Lamberti, G.; Plodkowski, A.; more...
The Oncologist (2023)

Fulltext@MSK | Save